Search Results - "Rusconi, Christopher"

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer by Ganson, Nancy J., PhD, Povsic, Thomas J., MD, Sullenger, Bruce A., PhD, Alexander, John H., MD, Zelenkofske, Steven L., DO, Sailstad, Jeffrey M., PhD, Rusconi, Christopher P., PhD, Hershfield, Michael S., MD

“…To the Editor: Nucleic acid aptamers are a novel class of drugs that can be selected to inhibit targets of interest, including protein-protein interactions.1…”
Get full text

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer by Povsic, Thomas J., MD, PhD, Lawrence, Monica G., MD, Lincoff, A. Michael, MD, Mehran, Roxana, MD, Rusconi, Christopher P., PhD, Zelenkofske, Steven L., DO, Huang, Zhen, MS, Sailstad, Jeffrey, BS, Armstrong, Paul W., MD, Steg, P. Gabriel, MD, Bode, Christoph, MD, Becker, Richard C., MD, Alexander, John H., MD, MHS, Adkinson, N. Franklin, MD, Levinson, Arnold I., MD

“…Murine models of anaphylaxis have suggested that IgG antibody/allergen complexes interacting with Fcγ receptors on basophils and neutrophils release…”
Get full text

Aptamers: an emerging class of therapeutics by Nimjee, Shahid M, Rusconi, Christopher P, Sullenger, Bruce A

“…Numerous nucleic acid ligands, also termed decoys or aptamers, have been developed during the past 15 years that can inhibit the activity of many pathogenic…”
Get full text

To PEGylate or Not To PEGylate Therapeutics? by Maier, Keith E, Rusconi, Christopher P, Levy, Matthew

“…PEGylation is a common modulator of pharmacokinetics for therapeutic agents in vivo. In this issue of Cell Chemical Biology, Moreno et al. (2019) show anti-PEG…”
Get more information

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics by Becker, Richard C, Povsic, Thomas, Cohen, Mauricio G, Rusconi, Christopher P, Sullenger, Bruce

“…Antithrombotic therapy for the acute management of thrombotic disorders has been stimulated and guided actively by our current understanding of platelet…”
Get more information

Antidote-mediated control of an anticoagulant aptamer in vivo by Rusconi, Christopher P, Sullenger, Bruce A, Roberts, Joseph D, Pitoc, George A, Nimjee, Shahid M, White, Rebekah R, Quick, George, Scardino, Elizabeth, Fay, William P

“…Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote…”
Get full text

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology : A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity by DYKE, Christopher K, STEINHUBL, Steven R, BECKER, Richard C, RUSCONI, Christopher P, KLEIMAN, Neal S, CANNON, Richard O, ABERLE, Laura G, MIN LIN, MYLES, Shelley K, MELLONI, Chiara, HARRINGTON, Robert A, ALEXANDER, John H

“…Selectivity, titratability, rapidity of onset, and active reversibility are desirable pharmacological properties of anticoagulant therapy administered for…”
Get full text

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention by COHEN, Mauricio G, PURDY, Drew A, ZELENKOFSKE, Steven, ALEXANDER, John H, HARRINGTON, Robert A, RUSCONI, Christopher P, BECKER, Richard C, ROSSI, Joseph S, GRINFELD, Liliana R, MYLES, Shelley K, ABERLE, Laura H, GREENBAUM, Adam B, FRY, Edward, CHAN, Mark Y, TONKENS, Ross M

“…The ideal anticoagulant should prevent ischemic complications without increasing the risk of bleeding. Controlled anticoagulation is possible with the REG1…”
Get full text

Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism by Eikelboom, John W, Zelenkofske, Steven L, Rusconi, Christopher P

“…Venous thromboembolism remains a frequent cause of vascular death. Despite advances in anticoagulant drug development, unmet needs remain, including limited…”
Get full text

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease by CHAN, Mark Y, COHEN, Mauricio G, VORCHHEIMER, David A, CHRONOS, Nicholas, MELLONI, Chiara, ALEXANDER, John H, HARRINGTON, Robert A, TONKENS, Ross M, BECKER, Richard C, RUSCONI, Christopher P, DYKE, Christopher K, MYLES, Shelley K, ABERLE, Laura G, MIN LIN, WALDER, James, STEINHUBL, Steven R, GILCHRIST, Ian C, KLEIMAN, Neal S

“…Whether selective factor IXa inhibition produces an appropriate anticoagulant effect when combined with platelet-directed therapy in patients with stable…”
Get full text

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes by Staudacher, Dawid L, Putz, Vera, Heger, Lukas, Reinöhl, Jochen, Hortmann, Marcus, Zelenkofske, Steven L, Becker, Richard C, Rusconi, Christopher P, Bode, Christoph, Ahrens, Ingo

“…Background: Residual platelet reactivity is a predictor of poor prognosis in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary…”
Get full text

Factor IXa Inhibitors as Novel Anticoagulants by Howard, Emily L, Becker, Kristian C.D, Rusconi, Christopher P, Becker, Richard C

“…Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced…”
Get full text

An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase by Buddai, Sai K., Layzer, Juliana M., Lu, Genmin, Rusconi, Christopher P., Sullenger, Bruce A., Monroe, Dougald M., Krishnaswamy, Sriram

“…The interaction of factor Xa with factor Va on membranes to form prothrombinase profoundly increases the rate of the proteolytic conversion of prothrombin to…”
Get full text

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial by Povsic, Thomas J., MD, PhD, Cohen, Mauricio G., MD, Mehran, Roxana, MD, Buller, Christopher E., MD, Bode, Christoph, MD, Cornel, Jan H., MD, Kasprzak, Jarosław D., MD, Montalescot, Gilles, MD, Joseph, Diane, Wargin, William A., PhD, Rusconi, Christopher P., PhD, Zelenkofske, Steven L., DO, Becker, Richard C., MD, Alexander, John H., MD, MHS

“…Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events…”
Get full text

In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry by Tanaka, Kenichi A, Szlam, Fania, Rusconi, Christopher P, Levy, Jerrold H

“…The REG1 system consists of factor IXa inhibitor, RB006, an aptamer-based anticoagulant and its antidote, RB007. The optimal use of RB006 can be facilitated by…”
Get more information

Inhibition of Rat Corneal Angiogenesis by a Nuclease-Resistant RNA Aptamer Specific for Angiopoietin-2 by White, Rebekah R., Shan, Siqing, Rusconi, Christopher P., Shetty, Geetha, Dewhirst, Mark W., Kontos, Christopher D., Sullenger, Bruce A.

“…Angiopoietin-2 (Ang2) appears to be a naturally occurring antagonist of the endothelial receptor tyrosine kinase Tie2, an important regulator of vascular…”
Get full text

Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX by White, Rebekah, Rusconi, Christopher, Scardino, Elizabeth, Wolberg, Alisa, Lawson, Jeffrey, Hoffman, Maureane, Sullenger, Bruce

“…Species cross-reactivity facilitates the preclinical evaluation of potentially therapeutic molecules in animal models. Here we describe an in vitro selection…”
Get full text

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy by Povsic, Thomas J., Wargin, William A., Alexander, John H., Krasnow, Joshua, Krolick, Merill, Cohen, Mauricio G., Mehran, Roxana, Buller, Christopher E., Bode, Christoph, Zelenkofske, Steven L., Rusconi, Christopher P., Becker, Richard C.

“…Aims Establishing factor IX inhibition in patients with acute coronary syndrome/non-ST-elevation myocardial infarction (ACS/NSTEMI), a setting characterized by…”
Get full text

Blocking the initiation of coagulation by RNA aptamers to factor VIIa by Rusconi, C P, Yeh, A, Lyerly, H K, Lawson, J H, Sullenger, B A

“…The tissue factor/factor VIIa complex is thought to be the primary initiator of most physiologic blood coagulation events. Because of its proximal role in this…”
Get more information

The potential of aptamers as anticoagulants by Nimjee, Shahid M., Rusconi, Christopher P., Harrington, Robert A., Sullenger, Bruce A.

“…Useful additional options for anticoagulant therapy have been introduced over the last 15 years, including low-molecular-weight heparins and direct thrombin…”
Get full text